The Molecular and Genetic Pathogenesis of LAM
LAM 的分子和遗传发病机制
基本信息
- 批准号:9914735
- 负责人:
- 金额:$ 87.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-21 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAllelesAlveolar CellAngiomyolipomaAutophagocytosisAwardBiogenesisBiological MarkersBloodCell DeathCell SurvivalCellsChronicClinicalClinical ResearchClinical TrialsCollaborationsCystDataData SetDevelopmentDiagnosticDiseaseDisease ProgressionDoctor of PhilosophyEnrollmentExtramural ActivitiesFRAP1 geneFibroblastsGene MutationGenesGeneticGoalsHumanImmunocompetentIn VitroInterleukin-6Intramural Research ProgramLongitudinal StudiesLoss of HeterozygosityLungLung LymphangioleiomyomatosisLymphangiogenesisLymphangioleiomyomatosisManuscriptsMetabolismMicroRNAsModelingMolecularMolecular GeneticsMonomeric GTP-Binding ProteinsMosaicismMossesMusMutationNew AgentsNodulePathogenesisPathway interactionsPatientsPatternPeer ReviewPharmaceutical PreparationsPhasePhenotypePlasmaPleural effusion disorderPreparationPrevalence StudyPrognostic MarkerProteinsProtocols documentationPublishingRenal AngiomyolipomaResearchResourcesRespiratory physiologyRiskSafetySerumSeveritiesSirolimusTSC2 geneTestingTherapeuticTherapeutic UsesToxic effectTuberous sclerosis protein complexUnited States National Institutes of HealthVascular Endothelial Growth Factor DWomanWorkalveolar destructionanalogapoAI regulatory protein-1celecoxibcell growthclinical centerclinical phenotypeclinically relevantdiagnostic biomarkerdisorder riskdosageearly detection biomarkersgenetic analysisgenome sequencinggenome wide association studyhigh riskhuman RNA sequencingin vivo Modelmembermodel developmentmouse modelnovelnovel markernovel therapeuticspersonalized carepersonalized medicineprogramsprotein complexrecruitresearch studyresponsesensorsingle-cell RNA sequencingtherapeutic targettumortumor-immune system interactionswhole genome
项目摘要
Abstract
Lymphangioleiomyomatosis (LAM) is a progressive multi-system disease of women characterized by
cystic lung destruction, renal angiomyolipomas, and chylous pleural effusions. Lymphangiogenesis is prominent
in pulmonary LAM nodules and serum VEGF-D levels above 800 pg/ml are a diagnostic biomarker of LAM. The
majority of LAM cells carry bi-allelic inactivating mutations in the tuberous sclerosis complex (TSC) genes and
circulating LAM cells with TSC2 loss of heterozygosity can be detected in the blood.
The TSC protein complex inhibits the mammalian/mechanistic target of rapamycin (mTORC1) via the
small GTPase Rheb. mTORC1 acts as a molecular sensor that regulates cell growth, metabolism, autophagy,
and microRNA biogenesis. Pivotal clinical trials have demonstrated clinical benefit from treatment with sirolimus
(Rapamycin) or its analogs (Rapalogs) in LAM and TSC. Collectively these data indicate that Rapamycin is an
effective suppressive therapy for LAM. However, lung function decline resumes, and tumors regrow when the
drug is discontinued. Therefore, therapy must be used chronically – perhaps lifelong. This highlights the urgent
unmet need for novel therapeutic strategies in LAM and TSC to eliminate (rather than suppress) LAM cells, for
novel biomarkers allowing personalization of therapy and to better understand genetic and clinical factors that
may help to predict the severity of LAM.
This UO1 brings together a unique team of leaders in lymphangioleiomyomatosis (LAM) and tuberous
sclerosis complex (TSC) to address key unanswered questions with high clinical impact. First, identifying novel
biomarkers of LAM. Using in vitro and in vivo models of LAM and single cell RNA sequencing from human LAM
lungs, systematic analysis of the LAM cell “secretome” will elucidate the pathogenesis of LAM revealing novel
prognostic biomarkers. Second, investigating novel mTORC1-independent pathways leading to LAM cell
survival that could be therapeutically targeted to induce LAM cell death. Third, analysis of genetic modifiers of
LAM and of potential cryptic generalized somatic mosaicism for TSC2 gene mutations to elucidate LAM
pathogenesis and help identify patients at highest risk of progression.
摘要
淋巴管平滑肌瘤病(LAM)是一种进行性多系统疾病的妇女,其特征在于
囊性肺破坏、肾血管平滑肌脂肪瘤和乳糜性胸腔积液。淋巴管生成突出
在肺LAM结节中,血清VEGF-D水平高于800 pg/ml是LAM的诊断生物标志物。的
大多数LAM细胞在结节性硬化症(TSC)基因中携带双等位基因失活突变,
可以在血液中检测到具有TSC 2杂合性缺失的循环LAM细胞。
TSC蛋白复合物通过免疫抑制剂抑制雷帕霉素的哺乳动物/机制靶标(mTORC 1)。
小GTtagh Rheb。mTORC 1作为一种分子传感器,调节细胞生长、代谢、自噬,
和microRNA的生物合成。初步临床试验已经证明西罗莫司治疗的临床获益
(雷帕霉素)或其类似物(雷帕霉素类似物)。总的来说,这些数据表明雷帕霉素是一种抗肿瘤药物。
有效的LAM抑制治疗。然而,肺功能下降恢复,肿瘤再生时,
药物停止。因此,治疗必须长期使用-也许是终身使用。这突出表明,
对LAM和TSC中消除(而不是抑制)LAM细胞的新型治疗策略的未满足需求,
新的生物标志物允许个性化治疗,并更好地了解遗传和临床因素,
可能有助于预测LAM的严重程度。
这个UO 1汇集了一个独特的领导团队,在淋巴管平滑肌瘤病(LAM)和结节性
硬化症(TSC),以解决具有高度临床影响的关键未回答的问题。第一,识别新的
LAM的生物标志物。使用LAM的体外和体内模型和来自人LAM的单细胞RNA测序
肺,系统分析LAM细胞的“分泌组”,将阐明LAM的发病机制,揭示新的
预后生物标志物。第二,研究新的mTORC 1非依赖性途径导致LAM细胞
可以在治疗上靶向以诱导LAM细胞死亡的存活。第三,基因修饰物分析,
LAM和TSC 2基因突变的潜在隐性广义体细胞嵌合体,以阐明LAM
发病机制,并帮助确定处于最高进展风险的患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Souheil El-Chemaly其他文献
Souheil El-Chemaly的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Souheil El-Chemaly', 18)}}的其他基金
The Molecular and Genetic Pathogenesis of LAM
LAM 的分子和遗传发病机制
- 批准号:
10359687 - 财政年份:2016
- 资助金额:
$ 87.77万 - 项目类别:
Effects of lymphangiogenesis stimulation on lung allograft rejection
刺激淋巴管生成对肺同种异体移植排斥反应的影响
- 批准号:
8570801 - 财政年份:2013
- 资助金额:
$ 87.77万 - 项目类别:
Intracellular Actions of the Lymphangiogenic Growth Factor VEGF-D in Fibroblasts
成纤维细胞中淋巴管生成因子 VEGF-D 的细胞内作用
- 批准号:
8545893 - 财政年份:2008
- 资助金额:
$ 87.77万 - 项目类别:
Intracellular Actions of the Lymphangiogenic Growth Factor VEGF-D in Fibroblasts
成纤维细胞中淋巴管生成因子 VEGF-D 的细胞内作用
- 批准号:
8535867 - 财政年份:2008
- 资助金额:
$ 87.77万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 87.77万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 87.77万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 87.77万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 87.77万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 87.77万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 87.77万 - 项目类别:
Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 87.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 87.77万 - 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 87.77万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 87.77万 - 项目类别: